Screener
Rigel Pharmaceuticals RIGL GAVRETO (pralsetinib) — Acquisition-related liabilities
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Rigel Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AssetAcquisitionContingentConsiderationLiabilityCurrent.
The source filing: Rigel Pharmaceuticals’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:05 PM EDT
- Fiscal quarter
- Q4 FY2026
- Calendar quarter
- Q4 2026
- Accession
- 0001034842-26-000032
| Line item | As of / March 31, 2026 | As of / December 31, 2025 ⁽¹⁾ |
|---|---|---|
| Accounts payable | $4,486 | $7,191 |
| Accrued compensation | 6,009 | 11,914 |
| Accrued research and development | 5,742 | 5,524 |
| Acquisition-related liabilities | 5,000 | 5,000 |
| Revenue reserves and refund liability | 28,080 | 27,716 |
| Loans payable, net, current portion | 29,865 | 29,812 |
| Other accrued liabilities | 9,674 | 11,466 |
| Lease liabilities, current portion | 636 | 614 |
Item 1. Financial Statements
FAQ
- What is Rigel Pharmaceuticals's GAVRETO (pralsetinib) — acquisition-related liabilities?
- Rigel Pharmaceuticals (RIGL) reported GAVRETO (pralsetinib) — acquisition-related liabilities of $5M in Q1 2026.
- What does GAVRETO (pralsetinib) — acquisition-related liabilities mean?
- This represents the balance sheet liabilities recognized as a result of the GAVRETO acquisition, such as contingent consideration or deferred payments. It reflects the ongoing financial obligations the company carries related to the asset's purchase. Investors monitor this to understand the company's leverage and future cash flow commitments.
Ask your AI about Rigel Pharmaceuticals's gavreto (pralsetinib) — acquisition-related liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude